X4 Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

Rhea-AI Summary

BOSTON, Sept. 01, 2021 - X4 Pharmaceuticals (Nasdaq: XFOR) announced its participation in investor meetings at the Citi 16th Annual BioPharma Conference from September 8-10, 2021 and a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM ET. A live webcast of the fireside chat will be available on the company's investor section of their website for 90 days post-event. X4 specializes in therapies targeting diseases related to the CXCR4 pathway, with its lead candidate mavorixafor under evaluation in multiple clinical trials.

BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will conduct one-on-one investor meetings at the Citi 16th Annual BioPharma Conference and participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference.

Details are as follows:

Conference: Citi 16th Annual BioPharma Conference
Date: September 8 – 10, 2021
1x1 meetings only

Conference: H.C. Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13, 2021
Time: 7:00 AM ET
Fireside Chat Webcast Link

A live webcast of the H.C. Wainwright 23rd Annual Global Investment Conference fireside chat will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com. The event will remain archived on the X4 Pharmaceuticals’ website for approximately 90 days.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases of the immune system resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a number of clinical trials, including a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström’s macroglobulinemia, and as monotherapy in patients with Severe Congenital Neutropenia and other chronic neutropenia disorders. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit www.x4pharma.com.

Investors and Media: 
Daniel Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Mónica Rouco Molina
Senior Account Executive
LifeSci Communications
mroucomolina@lifescicomms.com

FAQ

What dates will X4 Pharmaceuticals participate in the Citi BioPharma Conference?

X4 Pharmaceuticals will participate in the Citi 16th Annual BioPharma Conference from September 8-10, 2021.

When is the H.C. Wainwright Global Investment Conference for X4 Pharmaceuticals?

The H.C. Wainwright 23rd Annual Global Investment Conference for X4 Pharmaceuticals is scheduled for September 13, 2021, at 7:00 AM ET.

Where can I watch the X4 Pharmaceuticals fireside chat?

The fireside chat for X4 Pharmaceuticals can be watched via a live webcast on their investor section of the official website.

What is the focus of X4 Pharmaceuticals' research?

X4 Pharmaceuticals focuses on developing therapies for diseases related to the dysfunction of the CXCR4 pathway.

What is mavorixafor and its significance?

Mavorixafor is a first-in-class small molecule antagonist of the CXCR4 receptor, developed by X4 Pharmaceuticals for various diseases, including rare immunodeficiencies.